• Explore /
  • Poster
  • / Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.

Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.

Abstract Video & Slides Poster

Authors

Justin M. Watts

Justin M. Watts

Sylvester Cancer Center, Miami, FL

Justin M. Watts , Alessandro M. Vannucchi , Anthony Hunter , Brandon McMahon , Srinivas Kiran Tantravahi , Alessandra Iurlo , Blanca Xicoy , Francesca Palandri , Emma Searle , Brandi Reeves , Prithviraj Bose , Rosa Ayala Diaz , Anna B. Halpern , Xuejun Chen , Lea Micaletti Burke , Feng Zhou , Fred Zheng , Pankit Vachhani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT04279847

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 6576)

DOI

10.1200/JCO.2024.42.16_suppl.6576

Abstract #

6576

Poster Bd #

135

Abstract Disclosures

Similar Posters

First Author: Justin M. Watts

First Author: Jie Jin

First Author: Gregory Roloff

First Author: Wang Yk